Franklin Resources
CADL icon

Franklin Resources’s Candel Therapeutics CADL Stock Holding History

Franklin Resources’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-211,014
Closed -$1.19M – 3039
2025
Q1 		$1.19M Buy
+211,014
New +$1.72M ﹤0.01% 1885
2023
Q4 		– Sell
-1,125,000
Closed -$1.05M – 2650
2023
Q3 		$1.05M Hold
1,125,000
– – ﹤0.01% 1607
2023
Q2 		$1.42M Hold
1,125,000
– – ﹤0.01% 1526
2023
Q1 		$1.54M Hold
1,125,000
– – ﹤0.01% 1419
2022
Q4 		$2.01M Hold
1,125,000
– – ﹤0.01% 1363
2022
Q3 		$3.53M Hold
1,125,000
– – ﹤0.01% 1174
2022
Q2 		$3.65M Hold
1,125,000
– – ﹤0.01% 1182
2022
Q1 		$5.73M Hold
1,125,000
– – ﹤0.01% 1133
2021
Q4 		$8.8M Hold
1,125,000
– – ﹤0.01% 1099
2021
Q3 		$12.2M Buy
+1,125,000
New +$9.33M ﹤0.01% 1014

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Franklin Resources's CADL Position: Q2 2025 in Review

Franklin Resources sold out of Candel Therapeutics (CADL) in Q2 2025, closing a stake of 211,014 shares — an estimated $1.19M sold.

Franklin Resources first reported a position in CADL in Q3 2021 and held it in 10 quarters. The position peaked at $12.2M in Q3 2021. 78 funds tracked by Wall St. Rank hold CADL as of Q2 2025.

  • Franklin Resources reported no remaining Candel Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Franklin Resources sold 211,014 Candel Therapeutics shares in Q2 2025, an estimated $1.19M.
  • Franklin Resources first reported a position in Candel Therapeutics in Q3 2021 and held it in 10 quarters.
  • Franklin Resources's Candel Therapeutics position peaked at $12.2M in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2025.

Based on Franklin Resources's 13F filing for Q2 2025, filed 12 Aug 2025.